thumbnail image
broken image
broken image
broken image

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
    • OrCA
    • RaKSA
  • Team & Journey
  • Stay Abreast
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
      • OrCA
      • RaKSA
    • Team & Journey
    • Stay Abreast
Contact Us
broken image
broken image
broken image

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
    • OrCA
    • RaKSA
  • Team & Journey
  • Stay Abreast
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
      • OrCA
      • RaKSA
    • Team & Journey
    • Stay Abreast
Contact Us
broken image
  • Making Life Saving Breast Exams Accessible

    iBreastExamTM is an FDA cleared hand-held device enabling primary health workers to identify breast lumps early, in just a few minutes, without any pain or radiation

    Product Literature
  • Making Breast Exams Quick & Painless 

    radiation-free and easy, for women everywhere

  • How It Works

    1

    Breast Lumps

    Breast lumps (lesions) are stiffer than healthy breast tissue. Difference in their tissue elasticity is measurable

    2

    Tactile Imaging

    Dynamic Co-Planar Capacitive Sensors in iBreastExam measure these changes in real-time, digitally and non-invasively

    3

    Detection

    iBreastExam standardizes lump detection with minimal training and without requiring user interpretation 

    4

    Documentation

    Quick & painless documentation of routine breast exams inform and empower care providers and women alike

  • Independent Global Validations

    With over 25,000 Women Enrolled

    broken image

    In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.

    broken image

    iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.

     

    97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.

    broken image

    This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.

    broken image

    Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.

    broken image

    iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentation

  • Implementations & Posters

    India Study
    Large Scale Screening Study
    Brazil Study
  • News & Media

    UE Lifesciences on The New York Times

    Article

    TED Talks Shah Rukh Khan about UE LifeSciences

    Video

    UE LifeSciences on BBC News

    Video

    YourStory UE LifeSciences

    Article

    UE LifeSciences Featured on Forbes

    Article

Home

Journey

Team

Newsletter

+1.267.225.0453

info@UELifeSciences.com

iBreastExam

CervAIcal

OrCA

RaKSA

UE LifeSciences Inc. Copyright © 2024 | Terms & Conditions | Privacy Policy

    Home
    Innovation
    Call
    Email
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More